Medivation cancer drug impresses; shares double

An experimental prostate cancer drug from Medivation Inc helped patients live longer in a late-stage study, sending the company's shares soaring on hopes that it will become a strong contender in an estimated $9 billion market.

View full post on Yahoo! Health News

, , , , ,

Leave a Reply

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Get Adobe Flash player

Powered by Yahoo! Answers

© 1992-2012 DC2NET™, Inc. All Rights Reserved